Leah M. Grant

Leah M. Grant

Auto-generated profile, based on publicly available information

Leah M. Grant

Department of Infectious Diseases, HonorHealth, Scottsdale, Arizona, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2021 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
LGLeah Grant
Leah Grant
IMImran Mohamedy
Imran Mohamedy
LLLaura Loertscher
Laura Loertscher
A 70-year-old man presented to the emergency department with fevers, ankle edema and nausea following a presumed insect bite on his ankle 1 month prior. On examination, he was febrile and had left leg pain with passive range of motion. Laboratory studies revealed anemia, thrombocytopenia, acute kidney injury and elevated aminotransaminases. Due to his recent travel to the Northeastern United States, he was suspected of having a possible tick-borne illness. Serologies were positive for Borrelia burgdorferi, Anaplasma phagocytophilum and Babesia microti, and the patient was diagnosed with Lyme disease, babesiosis and anaplasmosis. He was treated with doxycyline, atovaquone and azithromycin, leading to resolution of symptoms. While co-infection with Lyme disease is common, infection with three tickborne illnesses at one time is relatively rare.

13 October 2024 in Transplant Infectious Disease
Verified
Journal Article
Closed access
LGLeah M. Grant
Leah M. Grant
PVPool J. Tobar Vega
Pool J. Tobar Vega
RYReena Nazek Yaman
Reena Nazek Yaman
MGMarlene E. Girardo
Marlene E. Girardo
EBElena Beam
Elena Beam
HVHolenarasipur Vikram
Holenarasipur Vikram

3 September 2022 in Journal of Investigative Medicine High Impact Case Reports
Verified
Journal Article
Open access
LGLeah M. Grant
Leah M. Grant
RORobert Orenstein
Robert Orenstein
Recurrent vulvovaginal candidiasis is a common disorder which causes significant morbidity among women worldwide, and treatment options are limited. Ibrexafungerp is a novel antifungal agent which was approved in 2021 for treatment of vulvovaginal candidiasis. We present a case of recurrent vulvovaginal candidiasis successfully treated with ibrexafungerp.

26 November 2024 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Open access
PDF file
DIDan Ilges
Dan Ilges
EGErin H. Graf
Erin H. Graf
LGLeah Grant
Leah Grant
ALAshley Long
Ashley Long
ESEric Siebeneck
Eric Siebeneck
LSLisa J. Speiser
Lisa J. Speiser
Objective: Multiplex polymerase chain reaction (PCR) panels for stool testing may be used to diagnose Clostridioides difficile, which can circumvent more appropriate targeted C. difficile testing, resulting in treatment of incidentally detected colonization. We sought to reduce C. difficile diagnosis via a gastrointestinal pathogen panel (GIPP).Design: Quasi-experimental, pre/post, retrospective cohort study from January 1, 2022, to January 31, 2024.Setting: Mayo Clinic Arizona—a single academic medical center and associated clinics.Patients: Adult patients receiving C. difficile testing and/or treatment.Methods: Preferred C. difficile testing consisted of glutamate dehydrogenase and toxin antigen immunoassay, followed by toxin gene testing for discrepant results. The GIPP contained 22 targets during the baseline period with C. difficile removed during the postintervention period. Surveys were provided to provider and nursing groups, separately, to identify C. difficile ordering practices and knowledge gaps.Results: At baseline, from January 1, 2022, to January 31, 2023, 2,772 GIPPs were completed for 2,307 unique patients (∼7 per day), primarily for outpatients (1,805 of 2,772, 65%). The most common positive target was C. difficile (517 of 1,018, 51%), which resulted in treatment for C. difficile infection in 94.9% (337 of 355) of cases. Following GIPP C. difficile target removal, GIPP orders decreased from 3.23 to 2.7 per 1,000 patient visits (P < .001). Prescribing of C. difficile treatments decreased in the postintervention period in inpatient and outpatient settings. There were no cases of delayed C. difficile diagnosis during the postintervention period.Conclusions: Removing C. difficile from the GIPP resulted in effective diagnostic and antimicrobial stewardship without resulting in delayed diagnoses.

6 October 2023 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
LGLeah M Grant
Leah M Grant
MSMaria T Seville
Maria T Seville
EGErin H Graf
Erin H Graf
HVHolenarasipur Vikram
Holenarasipur Vikram
A woman in her 50s presented with a 4-day history of left knee pain, erythema, swelling as well as malaise and rigours 1 month after undergoing a left knee meniscectomy. She was diagnosed with left native knee septic arthritis and underwent arthroscopic irrigation and debridement of the knee; cultures from synovial tissue grew Rhodococcus erythropolis. Rhodococcus spp are soil-dwelling and livestock-dwelling bacteria which occasionally cause disease in immunocompromised hosts. Infection in immunocompetent hosts is rare, and septic arthritis secondary to Rhodococcus erythropolis has not been reported previously.

1 January 2026 in Case Reports in Infectious Diseases
Verified
Journal Article
Open access
LGLeah Grant
Leah Grant
SASeth Assar
Seth Assar
FTFarhan Taghizadeh
Farhan Taghizadeh
JHJoann Hutto
Joann Hutto
NANeil M. Ampel
Neil M. Ampel
A 47‐year‐old healthy man developed disseminated coccidioidomycosis involving his mediastinal and cervical lymph nodes that was complicated by pericardial involvement despite continued fluconazole for primary pulmonary infection. Although he subsequently received an aggressive antifungal regimen with voriconazole and liposomal amphotericin B, he did not clinically improve until he underwent major debridement and drainage, highlighting the need for source‐control procedures in some cases of severe disseminated coccidioidomycosis.